The term "monitoring drug therapy" used in RCW
18.64.011(11) shall mean a review of the drug therapy regimen of patients by a pharmacist for the purpose of evaluating and rendering advice to the prescribing practitioner regarding adjustment of the regimen. Monitoring of drug therapy shall include, but not be limited to:
(1) Collecting and reviewing patient drug use histories;
(2) Measuring and reviewing routine patient vital signs including, but not limited to, pulse, temperature, blood pressure and respiration; and
(3) Ordering and evaluating the results of laboratory tests relating to drug therapy including, but not limited to, blood chemistries and cell counts, drug levels in blood, urine, tissue or other body fluids, and culture and sensitivity tests when performed in accordance with policies and procedures or protocols applicable to the practice setting, which have been developed by the pharmacist and prescribing practitioners and which include appropriate mechanisms for reporting to the prescriber monitoring activities and results.
[Statutory Authority: RCW
18.64.005 and chapter
18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-863-110, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW
18.64.005. WSR 87-18-066 (Order 207), § 360-12-150, filed 9/2/87. Statutory Authority: RCW
18.64.005 and
69.41.075. WSR 83-20-053 (Order 176), § 360-12-150, filed 9/29/83. Statutory Authority: RCW
18.64.005 and
69.41.240. WSR 83-10-013 (Order 174), § 360-12-150, filed 4/26/83.]